Key Points
- Redmile Group purchased 400,000 Attovia Therapeutics shares at $17 each, investing $6.8 million and increasing its position by 51.1% to 1.18 million shares.
- Attovia shares opened at $20.17 and were trading down 1.0%, within a 52-week range of $18.64 to $22.79.
- BlackRock raised its Attovia stake by 23.4% in the second quarter to 164,358 shares, valued at approximately $317,000.
Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) major shareholder Redmile Group, Llc bought 400,000 shares of the stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the acquisition, the insider owned 1,182,854 shares of the company's stock, valued at $20,108,518. This represents a 51.10% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Attovia Therapeutics Trading Down 1.0%
Shares of ATTO opened at $20.17 on Friday. Attovia Therapeutics, Inc. has a 52-week low of $18.64 and a 52-week high of $22.79.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. increased its stake in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO - Free Report) by 23.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company's stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.'s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.
Attovia Therapeutics Company Profile
(
Get Free Report)
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
